Compounding Pharmacies in Personal Injury: Legitimate Use vs. Fraud Red Flags

James Wong — Founder & Pharmacist, LienScripts | February 22, 2026 | 8 min read

Compounded topical medications — lidocaine, diclofenac, ketamine, and others in combination formulas — have genuine clinical applications in personal injury cases. But they're also the product category most commonly cited in no-fault pharmacy fraud suits. Here's how to distinguish legitimate compounding from the fraud patterns that trigger RICO exposure.

Why Compounding Appears in Both Legitimate PI Care and Fraud Cases

Compounding — the preparation of customized medications by a licensed pharmacist to meet a specific patient's needs — has a legitimate and important role in personal injury medicine. Patients recovering from serious musculoskeletal injuries, neuropathic pain, and TBI may benefit from combination topical formulations that aren't available as standard commercial products.

But compounded topical medications are also the most common product category in New York no-fault pharmacy fraud suits. GEICO, Allstate, and American Transit have repeatedly identified the same compounded topicals — Lidocaine 5% Ointment, Diclofenac Sodium Gel 3%, Diclofenac Sodium 2% Solution — as the concentrated billing products at the center of alleged fraud schemes.

Understanding the difference between legitimate compounding and fraud-pattern compounding is essential for PI attorneys evaluating pharmacy partners.

What Is Pharmaceutical Compounding?

Pharmaceutical compounding is the preparation of a medication tailored to a specific patient's needs, created by a licensed pharmacist outside of standard manufacturing processes. Compounding is permitted by state pharmacy practice acts and regulated by the FDA in specific circumstances.

In personal injury medicine, compounding is most commonly used to:

• Create combination topical formulas that combine multiple active ingredients not available in a single commercial product (e.g., a topical that combines a local anesthetic, an anti-inflammatory, and a muscle relaxant)
• Adjust concentration or formulation for patients who need a different dose than commercially available
• Create topical versions of medications that are only commercially available in oral form, when oral administration is contraindicated
• Prepare medications for patients with specific allergies or sensitivities that preclude commercial products

Compounding is, by definition, patient-specific. A compounded prescription should be created pursuant to a valid prescriber-patient relationship, based on the specific clinical needs of that patient, and dispensed only for that patient.

Legitimate Clinical Applications in PI Cases

Neuropathic Pain

Personal injury patients with nerve damage — from disc herniation compressing nerve roots, peripheral nerve injuries from lacerations, or neuropathic sequelae from TBI — may benefit from topical preparations that target localized nerve pain. Combination topicals containing local anesthetics (lidocaine or tetracaine), anti-inflammatories, and neuropathic agents (ketamine, amitriptyline) can provide localized relief with minimal systemic absorption.

Legitimate clinical indicators for compounded neuropathic pain topicals:

• Documented nerve involvement on imaging or neurological exam
• Prescriber notes discussing the rationale for topical over oral formulation
• Patient-specific concentration adjustments based on treatment response

Musculoskeletal Injuries

Soft tissue injuries — rotator cuff tears, lumbar strain, cervical strain — frequently involve both inflammatory and nociceptive pain components. A combination topical that delivers both anti-inflammatory and analgesic effects directly to the injury site may have clinical advantages over oral alternatives for patients with GI sensitivities.

Legitimate clinical indicators:

• Specific injury site identified and matched to application area
• Prescriber notes discussing the choice of topical vs. oral and the reasons for the specific formulation
• Monitoring for treatment response with documentation of outcomes

Post-Surgical Pain Management

After orthopedic procedures — spinal fusion, knee or shoulder surgery — compounded topicals may serve as part of a multimodal pain management approach that reduces reliance on systemic opioids.

The Fraud Pattern: How Legitimate Compounding Gets Weaponized

The same product categories — Lidocaine/Diclofenac topicals — that have genuine clinical applications become fraud indicators when they exhibit specific patterns:

1. Protocol-Driven Prescribing Regardless of Individual Need

In fraud cases, the same combination topical is prescribed to virtually every patient who comes through a clinic, regardless of their specific injury type, severity, or treatment response. A compound prescribed to every patient with a back sprain, a shoulder injury, a TBI, and a knee contusion identically is not individualized care — it is a billing protocol.

Legitimate indicator: Prescriptions vary among patients. Some get topical formulations; others get oral medications; others get a combination. The prescriber's notes explain why this patient, with this injury, needs this specific formulation.

Fraud indicator: The same two or three compounded topicals appear on nearly every patient chart across dozens of injury types, with no documented clinical rationale for why each individual patient specifically needs that formulation.

2. Extreme Formulary Concentration

A pharmacy where two or three compounded topicals represent 80% or more of all billing is not serving clinical diversity. Even in a patient population consisting entirely of auto accident victims, genuine clinical diversity would produce a range of prescriptions: oral anti-inflammatories, muscle relaxants, sleep aids for post-traumatic sleep disruption, anxiety medications for psychological trauma, specialty medications for neurological injuries.

The fraud signal: When insurer data analysts review billing patterns for a pharmacy, extreme concentration in a small number of cheap-to-compound, high-billing-rate topicals is the primary statistical trigger for RICO investigation.

3. Price Spread Between Acquisition and Billing

Compounded medications can be cheap to produce but billed at substantial amounts under the NY no-fault fee schedule. This spread creates the financial incentive for fraud — the pharmacy collects the billing rate while incurring only the manufacturing cost. Legitimate clinical use doesn't disappear because of this spread, but the existence of the spread makes the concentration pattern financially explicable as fraud.

4. No Legitimate Prescriber-Patient Relationship

In fraud schemes, compounded prescriptions may be issued by prescribers who have never examined the patient, who issue prescriptions pursuant to a predetermined protocol handed to them by the clinic, or who have financial arrangements with the pharmacy that motivate volume rather than clinical judgment. When a prescription cannot be traced to a real prescriber-patient relationship involving actual examination and individualized assessment, it fails the basic validity standard for any prescription.

How to Evaluate a Compounding Pharmacy Partner

For PI attorneys evaluating pharmacy partners that offer compounded formulations:

Ask about prescriber relationships: Does the pharmacy have any financial arrangement with any prescriber or clinic? A compounding pharmacy that pays for prescriptions through kickbacks to clinic operators is operating the fraud model.

Ask about formulary breadth: What percentage of the pharmacy's PI-related compounding volume consists of the top two or three products? Concentration above 50-60% for a single compound warrants inquiry.

Ask about individualization evidence: Can the pharmacy demonstrate that its compounded formulations are prescribed based on individualized clinical assessment? Are there varying concentrations, varying active ingredients, and varying dosing instructions across the patient population?

Ask about documentation standards: What patient records does the pharmacy maintain for each compounded prescription? Is there documentation of the prescriber's rationale for the compound over commercial alternatives?

LienScripts and Compounding

LienScripts-affiliated dispensing pharmacies fill compounded formulations when they are prescribed as part of individualized treatment plans. Compounding is a tool in the clinical toolkit, not a billing protocol.

The distinction between legitimate and fraudulent compounding has nothing to do with the active ingredients — Lidocaine and Diclofenac can both serve genuine clinical purposes. The distinction lies in whether the prescription was generated by an independent clinical judgment for this specific patient's documented needs, or by a financial arrangement designed to maximize billing volume.

Related Resources

• Why New York Personal Injury Pharmacies Keep Getting Sued
• How to Vet a Personal Injury Pharmacy Partner
• Why PI Pharmacy Owners Shouldn't Also Own PI Clinics
• What Is a No-Fault Clinic Controller?
• Muscle Relaxant Comparison for Injury Patients

[!SOURCE] FDA — Compounding and the FDA: Questions and Answers — FDA guidance on permissible pharmaceutical compounding, including the distinction between patient-specific compounding and manufacturing.